Molecular imaging can predict response to novel metastatic breast cancer treatment
Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of the
Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy.
Nearly two-thirds of invasive breast cancers are ER-positive, and endocrine therapy is the mainstay of treatment for these tumors because of its favorable toxicity profile and efficacy. Should cancer progress in these patients, however, salvage endocrine therapy with molecularly targeted agents or chemotherapy can help.
Date Time
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment
Reston, VA-Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called
18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy.
Nearly two-thirds of invasive breast cancers are ER-positive, and endocrine therapy is the mainstay of treatment for these tumors because of its favorable toxicity profile and efficacy. Should cancer progress in these patients, however, salvage endocrine therapy with molecularly targeted agents or chemotherapy can help.
Press release content from Business Wire. The AP news staff was not involved in its creation.
NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board
February 8, 2021 GMT
Regulatory News:
NOXXON Pharma N.V.
(Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the appointment of four leading pancreatic cancer experts to its Scientific Advisory Board (SAB). Led by the newly appointed Chair, Dr. Jose Saro, the SAB will provide strategic and scientific counsel to NOXXON’s clinical programs in this indication.
“These prominent research leaders bring long-standing clinical expertise, cutting-edge scientific knowledge, and a track record of successfully developing new drugs to treat this devastating disease. They fully understand the challenges of developing new drugs for pancreas cancer where the tumor microenvironment plays a large role in resisting ant
Are COVID-19 vaccines safe for cancer patients?
Despite the limited data, medical groups, doctors, and cancer experts are pushing for vaccination of most cancer patients
February 8, 2021 10:39 GMT
With an increasing number of individuals who are getting their COVID-19 vaccines, cancer patients are in a quandary on whether they should be vaccinated. Now, a number of cancer experts have weighed in on the issue.
The American Cancer Society (ACS) has revealed that there is a general consensus that vaccines are considered safe for most cancer patients. However, the health society admitted that there is still not much data on whether the vaccine will be effective for patients with cancer. What the body suggests is for cancer patients to discuss their options with their doctor.
Washington Mesothelioma Victims Center Urges a Power Plant Worker with Mesothelioma in Washington State to Call Attorney Erik Karst of Karst von Oiste-Get Much Better Compensation Results-That Might be Millions einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.